Ketamine Therapy Clinics in the United States: 2026 Statistical Analysis

Original data analysis of the ketamine therapy provider landscape across all 50 states and DC, compiled from the Spravato REMS registry and ASKP member directory.

Data compiled and analyzed by DrugsRegistry.com · Published April 16, 2026 · Licensed under CC BY 4.0

Key Findings

As of July 2026, this directory contains 4,215 source records across 51 states and the District of Columbia in the United States. Of these, 3,923 (93.1%) are current outpatient Spravato locator records, and 292 (6.9%) are current ASKP directory records. One organization can appear in both sources, so these figures should not be interpreted as a count of unique businesses. California leads in total records (394), while Nebraska has the highest per-capita density at 33.0 records per million residents.

Contents

  1. Data Sources and Methodology
  2. National Overview
  3. Providers by State
  4. Clinic Density Per Capita
  5. Top Cities
  6. Provider Specialties
  7. Data Source Breakdown
  8. How to Cite

1. Data Sources and Methodology

This analysis draws on two primary data sources:

  1. Spravato REMS Registry — The FDA-mandated Risk Evaluation and Mitigation Strategy registry of healthcare facilities certified to administer Spravato (esketamine) nasal spray. This registry is maintained by Janssen Pharmaceuticals and the FDA. It contains 3,923 certified treatment centers.
  2. ASKP Member Directory — The American Society of Ketamine Physicians, Psychotherapists, and Practitioners (ASKP) maintains a directory of its member clinics. This directory contains 292 member practices.

Records were cross-referenced using provider name, address, and NPI (National Provider Identifier) number to identify overlapping entries. 0 providers appear in both sources. After deduplication, the combined dataset contains 4,215 unique providers.

Provider credentials and specialties were verified against the CMS NPI Registry (NPPES) when NPI numbers were available. Population estimates are based on U.S. Census Bureau 2024 estimates.

This data represents certified and registered providers only. The actual number of practitioners offering ketamine therapy in the United States may be higher, as some providers administer ketamine without ASKP membership or Spravato certification (e.g., anesthesiologists providing off-label IV ketamine infusions).

2. National Overview

4,215 ketamine therapy providers across 51 states and DC

MetricCountPercentage
Total unique providers4,215100%
Spravato REMS-certified centers3,92393.1%
ASKP member clinics2926.9%
Listed in both registries00.0%
Spravato-only (not ASKP)3,92393.1%
ASKP-only (not Spravato-certified)2926.9%
States with at least one provider51100% of states

The dominance of Spravato REMS-certified centers (93.1% of all providers) reflects the growth of the FDA-approved pathway since esketamine’s approval in March 2019. ASKP member clinics, which more commonly offer IV ketamine infusions and ketamine-assisted psychotherapy (KAP), represent a smaller but clinically significant segment of the market.

3. Providers by State

All 51 states and the District of Columbia have at least one registered ketamine therapy provider. The top 5 states by total provider count are California (394), Texas (382), Florida (283), New York (217), and Illinois (170).

# State Total Providers Spravato ASKP Per 1M Pop.
1 California 394 352 42 10.1
2 Texas 382 352 30 12.5
3 Florida 283 261 22 12.5
4 New York 217 207 10 11.1
5 Illinois 170 166 4 13.6
6 Ohio 157 150 7 13.3
7 New Jersey 140 132 8 15.1
8 Arizona 133 119 14 18.0
9 North Carolina 119 114 5 11.1
10 Virginia 115 108 7 13.2
11 Massachusetts 112 107 5 16.0
12 Utah 102 99 3 30.0
13 Michigan 98 94 4 9.8
14 Maryland 98 96 2 15.8
15 Tennessee 98 93 5 13.8
16 Washington 96 84 12 12.3
17 Colorado 90 72 18 15.3
18 Pennsylvania 90 82 8 7.0
19 Indiana 85 81 4 12.3
20 Georgia 82 73 9 7.5
21 Kentucky 75 73 2 16.7
22 Missouri 74 73 1 11.9
23 Kansas 72 69 3 24.8
24 Iowa 70 65 5 21.9
25 Nebraska 66 63 3 33.0
26 Oklahoma 64 62 2 15.6
27 Louisiana 63 62 1 13.7
28 Connecticut 63 59 4 17.5
29 Arkansas 60 59 1 19.4
30 Oregon 54 50 4 12.9
31 Minnesota 50 47 3 8.8
32 South Carolina 46 42 4 8.5
33 Nevada 45 41 4 14.1
34 Alabama 44 39 5 8.6
35 Wisconsin 42 36 6 7.1
36 Idaho 39 33 6 19.5
37 Mississippi 33 32 1 11.4
38 West Virginia 30 30 0 16.7
39 New Hampshire 22 21 1 15.7
40 Montana 20 18 2 18.2
41 Rhode Island 17 16 1 15.5
42 New Mexico 16 13 3 7.6
43 Delaware 15 13 2 15.0
44 Maine 15 15 0 10.7
45 Alaska 14 14 0 19.2
46 South Dakota 12 12 0 13.2
47 Wyoming 10 5 5 17.2
48 North Dakota 7 6 1 9.0
49 Vermont 6 4 2 9.2
50 District of Columbia 5 4 1 7.2
51 Hawaii 5 5 0 3.6

4. Clinic Density Per Capita

Adjusting for population reveals a different geographic picture. States with the highest per-capita provider density are not necessarily the most populous. Nebraska leads with 33.0 providers per million residents, followed by Utah (30.0) and Kansas (24.8).

National average density: 12.6 providers per million residents (based on estimated 2024 US population of 335 million)

# State Per 1M Residents Total Providers Population (est.)
1 Nebraska 33.0 66 2.0M
2 Utah 30.0 102 3.4M
3 Kansas 24.8 72 2.9M
4 Iowa 21.9 70 3.2M
5 Idaho 19.5 39 2.0M
6 Arkansas 19.4 60 3.1M
7 Alaska 19.2 14 0.7M
8 Montana 18.2 20 1.1M
9 Arizona 18.0 133 7.4M
10 Connecticut 17.5 63 3.6M
11 Wyoming 17.2 10 0.6M
12 Kentucky 16.7 75 4.5M
13 West Virginia 16.7 30 1.8M
14 Massachusetts 16.0 112 7.0M
15 Maryland 15.8 98 6.2M

The lowest-density states are Hawaii (3.6 per 1M), suggesting that geographic isolation and market size limit provider availability. Patients in low-density states may need to travel to access ketamine therapy or consider telehealth-based oral ketamine programs.

5. Top Cities by Provider Count

Major metropolitan areas concentrate the most providers. New York City leads with 47 providers, followed by Houston (42) and San Antonio (36).

# City Total Providers Spravato ASKP
1 Houston, TX 47 43 4
2 New York, NY 42 40 2
3 San Antonio, TX 36 34 2
4 Omaha, NE 31 30 1
5 Austin, TX 30 23 7
6 Las Vegas, NV 25 23 2
7 Chicago, IL 24 23 1
8 Dallas, TX 23 23 0
9 Phoenix, AZ 22 19 3
10 San Diego, CA 22 20 2
11 Miami, FL 20 18 2
12 Tucson, AZ 20 19 1
13 Los Angeles, CA 19 17 2
14 Portland, OR 18 16 2
15 Tampa, FL 18 17 1
16 Sacramento, CA 17 15 2
17 Tulsa, OK 17 17 0
18 Lincoln, NE 16 15 1
19 Colorado Springs, CO 16 13 3
20 Indianapolis, IN 16 15 1

6. Provider Specialties

Of the 494 providers with NPI data available, the most common specialties are psychiatry, nurse practitioner (psychiatric), and anesthesiology. This reflects the multidisciplinary nature of ketamine therapy, which spans psychiatric, anesthesia, and primary care settings.

Specialty Count % of NPI-Verified
Psychiatry & Neurology, Psychiatry 134 27.1%
Nurse Practitioner, Psych/Mental Health 54 10.9%
Clinic/Center, Mental Health (Including Community Mental Health Center) 32 6.5%
Emergency Medicine 19 3.8%
Nurse Anesthetist, Certified Registered 17 3.4%
Anesthesiology 14 2.8%
Family Medicine 14 2.8%
Clinic/Center, Multi-Specialty 13 2.6%
Community/Behavioral Health 13 2.6%
Clinic/Center 10 2.0%

The presence of emergency medicine physicians (19) and family medicine practitioners (14) among ketamine providers indicates that ketamine therapy is not limited to psychiatric or anesthesia practices, though these remain the dominant specialties.

7. Data Source Overlap Analysis

The two primary data sources (Spravato REMS registry and ASKP directory) have limited overlap, indicating they capture distinct segments of the ketamine therapy market:

  • 3,923 providers (93.1%) appear only in the Spravato REMS registry — these are facilities certified to administer esketamine nasal spray but not ASKP members
  • 292 providers (6.9%) appear only in the ASKP directory — these typically focus on IV ketamine, IM ketamine, or KAP without Spravato certification
  • 0 providers (0.0%) appear in both sources — full-service ketamine clinics offering both Spravato and other ketamine modalities

The low overlap rate (0.0%) underscores that Spravato REMS centers and ASKP member clinics serve different market segments. Aggregating both sources is essential for a comprehensive picture of ketamine therapy availability in the United States.

8. How to Cite This Data

This data is published under a Creative Commons Attribution 4.0 (CC BY 4.0) license. You are free to share and adapt this data for any purpose, including commercial use, provided you give appropriate credit.

Suggested citation: DrugsRegistry.com. “Ketamine Therapy Clinics in the United States: 2026 Statistical Analysis.” Published April 16, 2026. https://drugsregistry.com/ketamine-clinics-statistics/. Accessed [date].

For researchers: This analysis is a dated snapshot compiled from the Spravato REMS and ASKP directories. ASKP is a voluntary membership directory, not a government registry, and every current status should be checked against the original source.

Data Sources

  1. Janssen Pharmaceuticals. Spravato treatment-center locator. official locator. Accessed July 2026; directory includes outpatient locations reporting treatment within the last six months.
  2. American Society of Ketamine Physicians, Psychotherapists, and Practitioners (ASKP). Member Provider Directory. official directory. Accessed July 2026.
  3. Centers for Medicare & Medicaid Services. National Plan and Provider Enumeration System (NPPES) NPI Registry. https://npiregistry.cms.hhs.gov/. Used for provider credential and specialty verification.
  4. U.S. Census Bureau. State Population Estimates, 2024. Used for per-capita density calculations.